PL2099784T3 - 1,5-difenylo-3-pirydynyloamino-1,5-dihydrioirrolidyn-2-ony jako modulatory receptora cb1 - Google Patents

1,5-difenylo-3-pirydynyloamino-1,5-dihydrioirrolidyn-2-ony jako modulatory receptora cb1

Info

Publication number: PL2099784T3
Authority: PL; Poland
Prior art keywords: dihydrioyrrolidin; pyridinylamino; diphenyl; ones; receptor modulators
Prior art date: 2006-10-23

Application number

PL07871196T

Other languages

English (en)

Inventor

John Mehnert Schaus

Perry Clark Heath

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-23

Filing date

2007-10-22

Publication date

2013-05-31

2007-10-22 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2013-05-31 Publication of PL2099784T3 publication Critical patent/PL2099784T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Nutrition Science (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL07871196T 2006-10-23 2007-10-22 1,5-difenylo-3-pirydynyloamino-1,5-dihydrioirrolidyn-2-ony jako modulatory receptora cb1 PL2099784T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US86254006P	2006-10-23	2006-10-23
EP07871196A EP2099784B1 (en)	2006-10-23	2007-10-22	1,5-diphenyl-3-pyridinylamino-1,5-dihydrioyrrolidin-2-ones as cb1 receptor modulators
PCT/US2007/082041 WO2008070305A2 (en)	2006-10-23	2007-10-22	1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as cbl' receptor modulator

Publications (1)

Publication Number	Publication Date
PL2099784T3 true PL2099784T3 (pl)	2013-05-31

Family

ID=39386481

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL07871197T PL2094684T3 (pl)	2006-10-23	2007-10-22	1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1
PL07871196T PL2099784T3 (pl)	2006-10-23	2007-10-22	1,5-difenylo-3-pirydynyloamino-1,5-dihydrioirrolidyn-2-ony jako modulatory receptora cb1

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL07871197T PL2094684T3 (pl)	2006-10-23	2007-10-22	1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1

Country Status (23)

Country	Link
US (2)	US8168659B2 (pl)
EP (2)	EP2094684B1 (pl)
JP (2)	JP5331001B2 (pl)
KR (2)	KR101088236B1 (pl)
CN (2)	CN101528733B (pl)
AR (1)	AR063497A1 (pl)
AT (1)	ATE492543T1 (pl)
AU (1)	AU2007329808B2 (pl)
BR (1)	BRPI0717347A2 (pl)
CA (2)	CA2667372C (pl)
CL (1)	CL2007003002A1 (pl)
CY (1)	CY1111140T1 (pl)
DE (1)	DE602007011495D1 (pl)
DK (2)	DK2099784T3 (pl)
EA (2)	EA015175B1 (pl)
ES (2)	ES2356025T3 (pl)
MX (2)	MX2009004054A (pl)
PE (1)	PE20080926A1 (pl)
PL (2)	PL2094684T3 (pl)
PT (2)	PT2094684E (pl)
SI (2)	SI2099784T1 (pl)
TW (1)	TW200825067A (pl)
WO (2)	WO2008070305A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200825067A (en) *	2006-10-23	2008-06-16	Lilly Co Eli	CB1 compounds
AU2009238444B2 (en) *	2008-04-22	2013-08-29	Eli Lilly And Company	1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
ES2390560T3 (es) *	2008-04-22	2012-11-14	Eli Lilly And Company	Compuestos de 1,5-difenil-pirrolidin-2-ona como ligandos CB-1
WO2010057000A2 (en) *	2008-11-13	2010-05-20	The Trustees Of Columbia University In The City Of New York	Neuraminidase inhibitors and uses thereof
ITTO20110641A1 (it) *	2010-07-15	2012-01-16	Oleg Iliich Epshtein	Composizioni farmaceutiche e metodi di trattamento
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US20240158384A1 (en) *	2020-12-14	2024-05-16	The Board Of Trustees Of The Leland Stanford Junior University	Cb2 receptor agonists
WO2023205180A1 (en)	2022-04-19	2023-10-26	Nurix Therapeutics, Inc.	Biomarkers for cbl, and compositions and methods for their use
WO2023250097A1 (en)	2022-06-22	2023-12-28	Nurix Therapeutics, Inc.	Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200533657A (en) *	2004-02-17	2005-10-16	Esteve Labor Dr	Substituted pyrazoline compounds, their preparation and use as medicaments
DK1725536T3 (da) *	2004-02-19	2009-02-16	Solvay Pharm Bv	Imidazolin-derivater med CB1-antagonistisk aktivitet
US20060035245A1 (en) *	2004-04-20	2006-02-16	Ason Brandon L	Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en)	2005-08-16	2007-02-22	Pharmacia & Upjohn Company Llc	Cannabinoid receptor ligands and uses thereof
TW200825067A (en) *	2006-10-23	2008-06-16	Lilly Co Eli	CB1 compounds

2007
- 2007-10-18 TW TW096139051A patent/TW200825067A/zh unknown
- 2007-10-18 AR ARP070104628A patent/AR063497A1/es unknown
- 2007-10-18 PE PE2007001418A patent/PE20080926A1/es not_active Application Discontinuation
- 2007-10-18 CL CL200703002A patent/CL2007003002A1/es unknown
- 2007-10-22 ES ES07871197T patent/ES2356025T3/es active Active
- 2007-10-22 CN CN2007800394514A patent/CN101528733B/zh not_active Expired - Fee Related
- 2007-10-22 CA CA2667372A patent/CA2667372C/en not_active Expired - Fee Related
- 2007-10-22 PL PL07871197T patent/PL2094684T3/pl unknown
- 2007-10-22 US US12/441,570 patent/US8168659B2/en not_active Expired - Fee Related
- 2007-10-22 ES ES07871196T patent/ES2398388T3/es active Active
- 2007-10-22 DE DE602007011495T patent/DE602007011495D1/de active Active
- 2007-10-22 CA CA2667210A patent/CA2667210C/en not_active Expired - Fee Related
- 2007-10-22 EA EA200970405A patent/EA015175B1/ru not_active IP Right Cessation
- 2007-10-22 CN CN2007800394497A patent/CN101528732B/zh not_active Expired - Fee Related
- 2007-10-22 EP EP07871197A patent/EP2094684B1/en not_active Not-in-force
- 2007-10-22 WO PCT/US2007/082041 patent/WO2008070305A2/en not_active Ceased
- 2007-10-22 DK DK07871196.7T patent/DK2099784T3/da active
- 2007-10-22 PT PT07871197T patent/PT2094684E/pt unknown
- 2007-10-22 JP JP2009533585A patent/JP5331001B2/ja not_active Expired - Fee Related
- 2007-10-22 WO PCT/US2007/082042 patent/WO2008070306A2/en not_active Ceased
- 2007-10-22 PT PT78711967T patent/PT2099784E/pt unknown
- 2007-10-22 SI SI200731118T patent/SI2099784T1/sl unknown
- 2007-10-22 EP EP07871196A patent/EP2099784B1/en not_active Not-in-force
- 2007-10-22 PL PL07871196T patent/PL2099784T3/pl unknown
- 2007-10-22 KR KR1020097008214A patent/KR101088236B1/ko not_active Expired - Fee Related
- 2007-10-22 MX MX2009004054A patent/MX2009004054A/es active IP Right Grant
- 2007-10-22 AU AU2007329808A patent/AU2007329808B2/en not_active Ceased
- 2007-10-22 AT AT07871197T patent/ATE492543T1/de active
- 2007-10-22 SI SI200730538T patent/SI2094684T1/sl unknown
- 2007-10-22 US US12/444,692 patent/US7998985B2/en not_active Expired - Fee Related
- 2007-10-22 BR BRPI0717347-4A2A patent/BRPI0717347A2/pt not_active IP Right Cessation
- 2007-10-22 DK DK07871197.5T patent/DK2094684T3/da active
- 2007-10-22 JP JP2009533586A patent/JP5331002B2/ja not_active Expired - Fee Related
- 2007-10-22 KR KR1020097008216A patent/KR101088229B1/ko not_active Expired - Fee Related
- 2007-10-22 EA EA200970404A patent/EA015745B1/ru not_active IP Right Cessation
- 2007-10-22 MX MX2009004053A patent/MX2009004053A/es active IP Right Grant
2011
- 2011-01-27 CY CY20111100093T patent/CY1111140T1/el unknown

Also Published As

Publication number	Publication date
CL2007003002A1 (es)	2008-06-06
AU2007329807A1 (en)	2008-06-12
KR101088236B1 (ko)	2011-11-30
US20100016375A1 (en)	2010-01-21
WO2008070305A2 (en)	2008-06-12
CN101528732A (zh)	2009-09-09
JP2010507589A (ja)	2010-03-11
EP2099784A2 (en)	2009-09-16
CA2667210C (en)	2013-09-24
CY1111140T1 (el)	2015-06-11
WO2008070305A3 (en)	2008-08-28
EP2094684A2 (en)	2009-09-02
EP2099784B1 (en)	2012-12-12
SI2099784T1 (sl)	2013-02-28
PT2099784E (pt)	2013-01-04
SI2094684T1 (sl)	2011-04-29
KR20090069316A (ko)	2009-06-30
AU2007329808A1 (en)	2008-06-12
MX2009004053A (es)	2009-04-27
TW200825067A (en)	2008-06-16
EA015175B1 (ru)	2011-06-30
EA015745B1 (ru)	2011-10-31
PL2094684T3 (pl)	2011-05-31
CA2667210A1 (en)	2008-06-12
AU2007329808B2 (en)	2013-11-07
MX2009004054A (es)	2009-04-27
CA2667372A1 (en)	2008-06-12
ATE492543T1 (de)	2011-01-15
CN101528733A (zh)	2009-09-09
US8168659B2 (en)	2012-05-01
KR101088229B1 (ko)	2011-11-30
PT2094684E (pt)	2011-01-28
CN101528733B (zh)	2013-10-16
PE20080926A1 (es)	2008-07-19
CN101528732B (zh)	2013-04-03
AR063497A1 (es)	2009-01-28
CA2667372C (en)	2013-09-03
US20090275618A1 (en)	2009-11-05
EA200970405A1 (ru)	2009-12-30
DK2099784T3 (da)	2013-01-14
EA200970404A1 (ru)	2009-10-30
WO2008070306A2 (en)	2008-06-12
WO2008070306A3 (en)	2008-07-31
BRPI0717347A2 (pt)	2014-01-14
JP5331001B2 (ja)	2013-10-30
ES2356025T3 (es)	2011-04-04
JP5331002B2 (ja)	2013-10-30
EP2094684B1 (en)	2010-12-22
DE602007011495D1 (de)	2011-02-03
US7998985B2 (en)	2011-08-16
KR20090071613A (ko)	2009-07-01
ES2398388T3 (es)	2013-03-15
DK2094684T3 (da)	2011-03-14
JP2010507590A (ja)	2010-03-11

Publication	Publication Date	Title
IL198990A0 (en)	2010-02-17	Cb1 receptor modulators
GB0623101D0 (en)	2006-12-27	Secure network architecture
IL201973A0 (en)	2010-06-16	3,3-spiroindolinone derivatives
IL191767A0 (en)	2008-12-29	Imidazoles as gaba-b receptor modulators
IL225694A0 (en)	2013-06-27	Compounds 6,5- dihydro-h1-pyridine-2-one
ZA201001797B (en)	2010-11-24	1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
SI2099784T1 (sl)	2013-02-28	1,5-difenil-3-piridinilamino-1,5-dihidrorirolidin-2-oni kot modulatorji receptorja cb1
GB0701992D0 (en)	2007-03-14	Grehlin Receptor Modulators
SI2356123T1 (sl)	2013-01-31	Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
ZA201004828B (en)	2011-03-30	Cannabinoid receptor modulators
IL188388A0 (en)	2008-04-13	Pyrazole derivatives as cb1 modulators
EP2202231A4 (en)	2011-09-28	2,3-DIHYDROIMINOISOINDOLE DERIVATIVE
AU2008207290A8 (en)	2009-09-17	Stirrup
GB0616467D0 (en)	2006-09-27	Network tunnelling
GB0622569D0 (en)	2006-12-20	Cannabinoid receptor modulators
ZA200806237B (en)	2009-05-27	Cannibinoid receptor modulators
GB0811212D0 (en)	2008-07-23	CB1 Receptor Modulators
IL194972A0 (en)	2009-08-03	2-alkoxy-3,4,5-trihydroxy-alkylamide-
ZA200904663B (en)	2010-05-26	CB1 receptor modulators
DE602006020489D1 (de)	2011-04-14	Cb1-rezeptormodulatoren
GB0719111D0 (en)	2007-11-07	T.m.2
GB0724096D0 (en)	2008-01-16	Cannabinoid receptor modulators
HK1122811A (en)	2009-05-29	Cannibinoid receptor modulators
GB0623853D0 (en)	2007-01-10	Receptor
GB0608516D0 (en)	2006-06-07	Receptor